Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Turchi

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|July 3, 2008
Diagnosis and management of primary aldosteronismMarco Boscaro, Vanessa Ronconi, Federica Turchi, et al.
Current Vascular Pharmacology|April 10, 2009
Management of primary aldosteronism: its complications and their outcomes after treatmentGilberta Giacchetti, Federica Turchi, Marco Boscaro, et al.
Clinical Endocrinology|November 9, 2010
Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronismVanessa Ronconi, Federica Turchi, Maria-Christina Zennaro, et al.
American Journal of Hypertension|August 19, 2011
Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertensionFederica Turchi, Vanessa Ronconi, Valentina di Tizio, et al.
Trends in Endocrinology and Metabolism: TEM|February 27, 2008
Adipose cell-adrenal interactions: current knowledge and future perspectivesVanessa Ronconi, Federica Turchi, Iwona J Bujalska, et al.
European Journal of Endocrinology|January 10, 2009
Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenomaGilberta Giacchetti, Vanessa Ronconi, Silvia Rilli, et al.
Current Vascular Pharmacology|October 26, 2011
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonistsVanessa Ronconi, Federica Turchi, Gloria Appolloni, et al.
Journal of Hypertension|December 5, 2006
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational studyGilberta Giacchetti, Vanessa Ronconi, Federica Turchi, et al.
Minerva Endocrinology|November 27, 2025
Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2)Maria E Malighetti, Fabio Vescini, Maria Carpentieri, et al.
The Journal of Infectious Diseases|December 19, 2008
CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patientsAlessandra Sacchi, Massimo Tempestilli, Federica Turchi, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Current Opinion in Endocrinology, Diabetes, and Obesity|July 3, 2008
Diagnosis and management of primary aldosteronismMarco Boscaro, Vanessa Ronconi, Federica Turchi, et al.
Current Vascular Pharmacology|April 10, 2009
Management of primary aldosteronism: its complications and their outcomes after treatmentGilberta Giacchetti, Federica Turchi, Marco Boscaro, et al.
Clinical Endocrinology|November 9, 2010
Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronismVanessa Ronconi, Federica Turchi, Maria-Christina Zennaro, et al.
American Journal of Hypertension|August 19, 2011
Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertensionFederica Turchi, Vanessa Ronconi, Valentina di Tizio, et al.
Trends in Endocrinology and Metabolism: TEM|February 27, 2008
Adipose cell-adrenal interactions: current knowledge and future perspectivesVanessa Ronconi, Federica Turchi, Iwona J Bujalska, et al.
European Journal of Endocrinology|January 10, 2009
Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenomaGilberta Giacchetti, Vanessa Ronconi, Silvia Rilli, et al.
Current Vascular Pharmacology|October 26, 2011
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonistsVanessa Ronconi, Federica Turchi, Gloria Appolloni, et al.
Journal of Hypertension|December 5, 2006
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational studyGilberta Giacchetti, Vanessa Ronconi, Federica Turchi, et al.
Minerva Endocrinology|November 27, 2025
Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2)Maria E Malighetti, Fabio Vescini, Maria Carpentieri, et al.
The Journal of Infectious Diseases|December 19, 2008
CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patientsAlessandra Sacchi, Massimo Tempestilli, Federica Turchi, et al.
Pageof 4